Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia

Arnaud Petit; Amélie Trinquand; Sylvie Chevret; Paola Fabiola Ballerini; Jean‐Michel Cayuela; Nathalie Grardel; Aurore Touzart; Benoît Brethon; Hélène Lapillonne; Claudine Schmitt; Sandrine Thouvenin; Gérard P. F. Michel; Claude Preudhomme; Jean Pierre Soulier; Judith Landman‐Parker; Guy Leverger; Elizabeth A. Macintyre; André Baruchel; Vahid Asnafi

doi:10.1182/blood-2017-04-778829

Abstract

Key Points In pediatric T-ALL, oncogenetic markers, MRD, and WBC count are independent predictors of outcome. These factors should be used together for individual treatment stratification.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Petit et al. (2017) studied this question.

synapsesocial.com/papers/6ab5f6a81b6e853d2aad6402 https://doi.org/10.1182/blood-2017-04-778829

View at Publisher

Ask AI

Bookmark

Abstract

Key Points In pediatric T-ALL, oncogenetic markers, MRD, and WBC count are independent predictors of outcome. These factors should be used together for individual treatment stratification.

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia

Abstract

Discussion

Cite This Study

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia

Abstract

Discussion

Cite This Study

Keep reading

Keep reading